Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
Clinical trial NCT04068519 · COMPLETED
Trial details
- NCT number
- NCT04068519
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-28
- Primary completion
- 2018-12-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.